• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An open label clinical trial of thalidomide in NSAIDs refractory ankylosing spondylitis.

作者信息

Choudhury Minhaj Rahim, Hassan M Masudul, Kabir M Ekramul, Rabbani M Golam, Haq Syed Atiqul, Rahman Md Kasedur

机构信息

a Department of Rheumatology , Bangabandhu Sheikh Mujib Medical University , Dhaka , Bangladesh.

b Department of Medicine , Kurmitola General Hospital, Dhaka Cantonment , Dhaka , Bangladesh.

出版信息

Mod Rheumatol. 2018 Jul;28(4):730-732. doi: 10.1080/14397595.2018.1427430. Epub 2018 Feb 2.

DOI:10.1080/14397595.2018.1427430
PMID:29327635
Abstract
摘要

相似文献

1
An open label clinical trial of thalidomide in NSAIDs refractory ankylosing spondylitis.
Mod Rheumatol. 2018 Jul;28(4):730-732. doi: 10.1080/14397595.2018.1427430. Epub 2018 Feb 2.
2
One-year open-label trial of thalidomide in ankylosing spondylitis.沙利度胺治疗强直性脊柱炎的一年开放标签试验。
Arthritis Rheum. 2002 Jun 15;47(3):249-54. doi: 10.1002/art.10396.
3
Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial.沙利度胺治疗重度难治性强直性脊柱炎：一项为期6个月的开放标签试验。
J Rheumatol. 2003 Dec;30(12):2627-31.
4
[The efficacy and safety of long-term thalidomide in the treatment of ankylosing spondylitis].长期使用沙利度胺治疗强直性脊柱炎的疗效与安全性
Zhonghua Nei Ke Za Zhi. 2010 Aug;49(8):667-70.
5
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.阿那白滞素治疗活动性强直性脊柱炎24周的开放标签试验。
Ann Rheum Dis. 2005 Feb;64(2):296-8. doi: 10.1136/ard.2004.023176. Epub 2004 Jun 18.
6
Thalidomide in ankylosing spondylitis.沙利度胺治疗强直性脊柱炎
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S158-61.
7
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial.皮下注射甲氨蝶呤治疗活动期强直性脊柱炎无效：一项为期16周的开放标签试验。
Ann Rheum Dis. 2007 Mar;66(3):419-21. doi: 10.1136/ard.2006.054098. Epub 2006 Aug 10.
8
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).乌司奴单抗治疗活动期强直性脊柱炎患者的 28 周前瞻性开放标签概念验证研究（TOPAS）结果。
Ann Rheum Dis. 2014 May;73(5):817-23. doi: 10.1136/annrheumdis-2013-204248. Epub 2014 Jan 3.
9
Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis.沙利度胺治疗难治性强直性脊柱炎的疗效
Arthritis Rheum. 1999 Mar;42(3):580-1. doi: 10.1002/1529-0131(199904)42:3<580::AID-ANR27>3.0.CO;2-D.
10
Clinical research for curing ankylosing spondylitis through combining etanercept, thalidomide and sulfasalazine.通过联合使用依那西普、沙利度胺和柳氮磺胺吡啶治疗强直性脊柱炎的临床研究。
Pak J Pharm Sci. 2015 Jan;28(1 Suppl):359-62.

引用本文的文献

1
Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh.沙利度胺与柳氮磺胺吡啶治疗中重度强直性脊柱炎的疗效和安全性比较：一项来自孟加拉国的真实世界研究
Cureus. 2025 Jun 17;17(6):e86211. doi: 10.7759/cureus.86211. eCollection 2025 Jun.
2
Clinical Significance of Peripheral Blood Th1 and Th17 Cell Content and Serum IL-35 and IL-17 Expression in Patients with Ankylosing Spondylitis.强直性脊柱炎患者外周血Th1和Th17细胞含量及血清IL-35和IL-17表达的临床意义
Evid Based Complement Alternat Med. 2022 May 18;2022:6540557. doi: 10.1155/2022/6540557. eCollection 2022.